Cargando…

Benefits and Challenges of Inhibiting EZH2 in Malignant Pleural Mesothelioma

SIMPLE SUMMARY: Malignant pleural mesothelioma (MPM) is an aggressive cancer linked to asbestos exposure with an extremely poor outcome. Despite the recent approval of immune checkpoint blockade-based therapies, MPM still remains a fatal cancer that challenges physicians and scientists. Enhancer of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Al Khatib, MHD Ouis, Pinton, Giulia, Moro, Laura, Porta, Chiara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10000483/ https://www.ncbi.nlm.nih.gov/pubmed/36900330 http://dx.doi.org/10.3390/cancers15051537

Ejemplares similares

Expression and therapeutic significance of estrogen receptor β in malignant pleural mesothelioma
por: Pinton, Giulia, et al.
Publicado: (2017)

Inhibition of the Histone Methyltransferase EZH2 Enhances Protumor Monocyte Recruitment in Human Mesothelioma Spheroids
por: Mola, Silvia, et al.
Publicado: (2021)

CDKN2A Determines Mesothelioma Cell Fate to EZH2 Inhibition
por: Pinton, Giulia, et al.
Publicado: (2021)

Perifosine as a Potential Novel Anti-Cancer Agent Inhibits EGFR/MET-AKT Axis in Malignant Pleural Mesothelioma
por: Pinton, Giulia, et al.
Publicado: (2012)

Corrigendum: CDKN2A determines mesothelioma cell fate to EZH2 inhibition
por: Pinton, Giulia, et al.
Publicado: (2022)

Tissue transglutaminase (TG2) enables survival of human malignant pleural mesothelioma cells in hypoxia
por: Zonca, Sara, et al.
Publicado: (2017)

Diagnostic and Therapeutic Challenges of Malignant Pleural Mesothelioma
por: Moro, Jacopo, et al.
Publicado: (2022)

SIRT1 at the crossroads of AKT1 and ERβ in malignant pleural mesothelioma cells
por: Pinton, Giulia, et al.
Publicado: (2016)

Agonist activation of estrogen receptor beta (ERβ) sensitizes malignant pleural mesothelioma cells to cisplatin cytotoxicity
por: Pinton, Giulia, et al.
Publicado: (2014)

Editorial: Focus on malignant pleural mesothelioma immunology and immunotherapy
por: Porta, Chiara, et al.
Publicado: (2023)

Intracellular lactate-mediated induction of estrogen receptor beta (ERβ) in biphasic malignant pleural mesothelioma cells
por: Manente, Arcangela G., et al.
Publicado: (2015)

PARP1 inhibition affects pleural mesothelioma cell viability and uncouples AKT/mTOR axis via SIRT1
por: Pinton, Giulia, et al.
Publicado: (2013)

Unsymmetric Cisplatin-Based Pt(IV) Conjugates Containing a PARP-1 Inhibitor Pharmacophore Tested on Malignant Pleural Mesothelioma Cell Lines
por: Gabano, Elisabetta, et al.
Publicado: (2021)

Malignant pleural mesothelioma
por: Rao, Sukhesh
Publicado: (2009)

Metformin Induces Apoptosis and Inhibits Notch1 in Malignant Pleural Mesothelioma Cells
por: Rossini, Marika, et al.
Publicado: (2021)

Estrogen Receptor β Exerts Tumor Repressive Functions in Human Malignant Pleural Mesothelioma via EGFR Inactivation and Affects Response to Gefitinib
por: Pinton, Giulia, et al.
Publicado: (2010)

Circulating biomarkers in malignant pleural mesothelioma
por: Viscardi, Giuseppe, et al.
Publicado: (2020)

Malignant pleural mesothelioma with resolution of pleural effusion
por: Nishida, Sayaka, et al.
Publicado: (2023)

Malignant pleural mesothelioma in Italy
por: Bianchi, Claudio, et al.
Publicado: (2009)

Heterogeneity in Malignant Pleural Mesothelioma
por: Oehl, Kathrin, et al.
Publicado: (2018)

Immunotherapy in Malignant Pleural Mesothelioma
por: de Gooijer, Cornedine J., et al.
Publicado: (2020)

Malignant pleural mesothelioma: an update
por: Hajj, Glaucia N. M., et al.
Publicado: (2021)

Malignant pleural mesothelioma in situ
por: Ando, Kohei, et al.
Publicado: (2022)

Identification of Overexpressed Genes in Malignant Pleural Mesothelioma
por: Morani, Federica, et al.
Publicado: (2021)

Calcitriol Inhibits Viability and Proliferation in Human Malignant Pleural Mesothelioma Cells
por: Gesmundo, Iacopo, et al.
Publicado: (2020)

SMO mutations confer poor prognosis in malignant pleural mesothelioma
por: Signorelli, Diego, et al.
Publicado: (2020)

KRAS signaling in malignant pleural mesothelioma
por: Marazioti, Antonia, et al.
Publicado: (2021)

Cerebral metastasis from malignant pleural mesothelioma
por: El Molla, Mohamed, et al.
Publicado: (2013)

Malignant Pleural Mesothelioma: Genetic and Microenviromental Heterogeneity as an Unexpected Reading Frame and Therapeutic Challenge
por: Abbott, David Michael, et al.
Publicado: (2020)

Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition
por: Srinivasan, Gayathri, et al.
Publicado: (2017)

Metabolic rewiring and redox alterations in malignant pleural mesothelioma
por: Urso, Loredana, et al.
Publicado: (2019)

Thoracoscopy in Pleural Malignant Mesothelioma Diagnosis
por: Tassi, G. F., et al.
Publicado: (1997)

Imaging in staging of malignant pleural mesothelioma
por: Truong, Mylene T, et al.
Publicado: (2004)

Hedgehog Signaling in Malignant Pleural Mesothelioma
por: Felley-Bosco, Emanuela, et al.
Publicado: (2015)

Targeting YAP in malignant pleural mesothelioma
por: Zhang, Wen‐Qian, et al.
Publicado: (2017)

Multimodality treatment of malignant pleural mesothelioma
por: Berzenji, Lawek, et al.
Publicado: (2018)

Modern management of malignant pleural mesothelioma
por: Patel, Shivani C, et al.
Publicado: (2016)

Pleural tuberculosis mimicking malignant mesothelioma
por: Dawood, Wajahat, et al.
Publicado: (2019)

Cytomegalovirus infection in malignant pleural mesothelioma
por: Hunter-Schlichting, DeVon, et al.
Publicado: (2021)

Immunotherapeutic Approaches in Malignant Pleural Mesothelioma
por: Terenziani, Rita, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rang1ioc2vvc7plt8lfvvt0p91